Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"

08 March 2012

We have completed our review of an application for general reimbursement for Valsartan/Hydrochlorothiazide "Actavis".

The product is neither eligible for general nor general conditional reimbursement.

Valsartan/Hydrochlorothiazide "Actavis" is used for the treatment of hypertension.

When we compare Valsartan/Hydrochlorothiazide "Actavis" with the combination of losartan and hydrochlorothiazide, we assess that the price of the medicine is not reasonable relative to its therapeutic value.

Please find the Reimbursement Committee recommendation and our decision in the box to the right (in Danish only).

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.